For high-risk soft-tissue sarcomas (HR-STS) in adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival. Systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS. This short article summarises the results of this combination with regional hyperthermia (RHT) as a targeted treatment strategy.
strategies are needed to improve outcome with regard to local control and overall survival. Systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS. This short article summarises the results of this combination with regional hyperthermia (RHT) as a targeted treatment strategy.
The optimal treatment for HR-STS in adults remains a challenge for the multidisciplinary approach in modern oncology. Patients with large primary or recurrent STS (>5cm in diameter, grade 2-3) remain at increased risk of distant metastases and tumour-related mortality. Nearly all deaths are due to metastatic disease (e.g. lung, liver). The tendency for early haematogenous spread of STS may explain why distant metastases still occur in these patients despite optimal local treatment. Also, the invasiveness or anatomical location of locally advanced tumours often prevents resection with adequate margins, and the toxicity of radiotherapy limits the use of potentially therapeutic doses with a negative impact on local control.
Innovative Treatment Strategy
With regard to prognostic factors, it can be concluded that for each histologically distinct sarcoma the tendency for metastatic spread depends on high-risk factors such as the grade, size and depth of the tumour. 1,2 Therefore, treatment of STS is almost always multidisciplinary and should involve a team approach in order to optimise interaction between disciplines. Among the treatment modalities, surgery combined with radiation is of key importance, at least for local control. Although small, superficial and low-grade STS A programme of aggressive chemotherapy interdigitated with radiotherapy for patients with large, high-grade extremity sarcomas used as neoadjuvant chemotherapy mesna-doxorubicin-ifosfamidedacarbazine (MAID) with split-course radiotherapy followed by resection and post-operative adjuvant MAID chemotherapy. 4 On the basis of these data, the Radiation Therapy Oncology Group (RTOG) initiated a phase II trial to evaluate the efficacy and toxicity of a modified MAID regimen in similar patients in a multi-institutional setting. Efficacy results showed three-year rates for disease-free and overall survival of 56.5, 64.5 and 75.1%, respectively, but 83% of patients experienced grade 4 toxicities and another 5% fatal grade 5 toxicities. 5 The only randomised trial of neoadjuvant chemotherapy for patients with resectable, high-risk sarcoma was performed by the European Hyperthermic Therapy 7.3 years there was no statistically significant advantage in disease-free survival due to the lack of statistical power. 6 
Regional Hyperthermia Combined with Chemotherapy
The application of hyperthermia has been integrated into multimodal treatment strategies over the past 10-20 years. However, more recently designed applicators for controlled, superficial and deep heating under clinical conditions now allow clinicians to use hyperthermia combined with systemic chemotherapy or local radiotherapy as a matter of routine. 7 The rationale for the combination of cytotoxic drugs with RHT (increase of tumour temperature in the range of 40-44°C) in the treatment of STS is based on experimental and clinical evidence suggesting that heat increases killing of tumour cells by direct thermal toxicity, as well as evidence of thermal enhancement of drug efficacy. In addition, pre-clinical results indicate that hyperthermia might be useful in modulating the immune system by inducing the expression and release of heat-shock proteins. 8 The sarcoma group at the Klinikum Grosshadern Medical Center (KGMC) has focused its interest on the use of RHT as a new treatment modality for locally advanced HR-STS. The first results were obtained from a phase II study in 38 adult patients, mainly with STS. 9 These patients had relapsed after prior surgery and radiation and had not responded to previous chemotherapy alone. The local response rate was 37%. A drug combination of ifosfamide and etoposide (VP16) was used, combined with RHT as a second-line treatment. In addition to long-term tumour control in a subgroup of patients, the analysis of tumour temperatures (e.g. T 20 , T 50 , T 90 ) achieved using an electromagnetic deep regional heating device (BSD Medical Corporation system; see Figure 1 ) 10 showed significantly higher temperature parameters in responders compared with non-responders. Two additional consecutive phase II studies have been performed including extremity and non-extremity HR-STS (chemo-naïve patients). In the first study (RHT-91 protocol), 59 patients received four cycles of etoposide-ifosfamide-doxorubicin (EIA) combined with concurrent hyperthermia. The aim was to achieve a maximum tumour temperature of 42°C or higher for a period of 60 minutes. After this treatment, those patients whose tumour was judged to be resectable underwent surgery.
If the tumour showed signs of response, four additional cycles of combined chemotherapy and RHT were given. All patients not previously irradiated also received external-beam radiotherapy. Treatment-related toxicity was acceptable. The median survival was 52 months and the fiveyear survival rate was 49% (95% CI 36-61%) -values that are quite impressive in this group of patients. The data are in favour of patients responding to EIA combined with hyperthermia. 11 In the second study (RHT-95), a similar high-risk patient group (54 patients) received the same treatment as in the RHT-91 protocol, with the exception that the patients did not receive post-operative hyperthermia but were administered with systemic chemotherapy alone after surgery.
This study showed an inferior local failure-free survival rate compared with the RHT-91 protocol, but no difference was found in overall survival. 12 Thus, post-surgical hyperthermia combined with chemotherapy was revealed to be critical for local control. In another retrospective analysis for retroperitoneal and visceral STS recruited to both studies, the RHT-91 and RHT-95 protocols demonstrated that the initial response to chemotherapy combined with RHT was predictive of long-term survival. 13 Most recently, under the auspices of the EORTC and the European Society of Hyperthermic Oncology (ESHO), we were able to complete a randomised intergroup phase III trial (EORTC 62961/ESHO RHT-95) of multimodal treatment in patients with primary (S1 group) and recurrent (S2 group) disease or after inadequate surgery (S3 group: resections with HR-STS to extremity and non-extremity received neoadjuvant systemic chemotherapy (four cycles of the EIA regimen) and were randomised to one of two arms -chemotherapy alone or combined with RHT -followed by definitive surgery and radiotherapy. Thereafter, in addition, four cycles of the EIA regimen were administered with or without RHT, according to the initial randomisation (see Figure 2) . The first interim report showed promising results in terms of overall outcome for extremity and nonextremity STS. 14 We also analysed the risk of early progression for the three-month duration of pre-operative therapy after recruitment of more than 250 patients. Delay of surgical resection due to this period of initial management is of major concern. A total of 213 patients were eligible for assessment of early progression. The aim was to achieve a maximum tumour temperature of 42°C or higher for a period of 60 minutes. After this treatment, those patients whose tumour was judged to be resectable underwent surgery.
